Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial
Zinzani Pier, Khuageva, Wang Huaqing, Garicochea Bernardo, Walewski Jan, Van, Pierre Soubeyran, Caballero Dolores, Buckstein Rena, Esseltine Dixie-Lee, Theocharous Panteli, Enny Christopher, Zhu Eugene, Elsayed, Coiffier Bertrand